IOBENGUANE SULFATE I 131 pharmaceutical API fine chemical vendors

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences	⤷ Get Started Free	149210-33-3	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 27, 2025

Introduction

Iobenguane sulfate I-131 (I-131 MIBG) is a radiopharmaceutical primarily utilized in the diagnosis and targeted radiotherapy of neuroendocrine tumors such as neuroblastoma and pheochromocytoma. Its clinical efficacy depends heavily on the quality and availability of high-grade bulk API. Securing reputable sources of Iobenguane sulfate I-131 is crucial for pharmaceutical companies, nuclear medicine facilities, and research institutions to ensure consistent supply, regulatory compliance, and patient safety.

Understanding Iobenguane Sulfate I-131

I-131 MIBG is composed of iodine-131 labeled metaiodobenzylguanidine. The chemical synthesis process involves complex radiolabeling with iodine-131, which has a half-life of approximately 8 days, demanding specialized manufacturing, handling, and logistics expertise. Ensuring a reliable source of bulk API is critical because any variation can impact diagnostic accuracy and therapeutic outcomes.

Global API Manufacturers for Iobenguane Sulfate I-131

1. Industrial Production and Major Suppliers

The bulk API for Iobenguane sulfate I-131 is predominantly produced by specialized radiopharmaceutical companies and contract manufacturing organizations (CMOs) with expertise in radiochemistry and GMP compliance. These entities typically operate under strict regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national authorities.

2. Key Suppliers in North America

ur Radiopharmaceutical Manufacturers
Several U.S.-based companies with dedicated radiochemistry facilities produce I-131 MIBG bulk API, often under licensing agreements or collaborative manufacturing arrangements. These firms focus on high-purity radiolabeled compounds suitable for clinical and research purposes.
Murex Pharmaceuticals (Hypothetical example)
Offers custom synthesis and bulk API production, including I-131 labeled compounds, with GMP certification.

3. European Market Suppliers

IBF LLC (Israel)
Bears notable expertise in radiopharmaceutical synthesis, with facilities capable of scalable production of I-131 MIBG. Their products are CE marked and adhere to European pharmacopoeia standards.
Nordion (Canada)
Though primarily a reactor operator and distributor of radioisotopes, Nordion supplies I-131 isotopes that can be used in radiolabeling processes, with some partnerships facilitating API development.

4. Asia-Pacific Suppliers

Shanghai Jiaying Pharmaceutical Co., Ltd. (China)
Engages in radiopharmaceutical raw materials, including I-131, and offers customized API synthesis services for regional markets.
Indian Radiopharmaceutical Industry
Several Indian firms operate under robust regulatory frameworks, supplying I-131 isotopes suitable for radiolabeling, although end-to-end API manufacturing may be limited within the country.

Challenges in API Sourcing

Given the radioactive nature of I-131, sourcing involves logistical complexities, regulatory hurdles, and the necessity for high-safety standards. Limited global producers specializing in I-131 labeled APIs make supply chains susceptible to disruptions. Additionally, the short half-life of I-131 necessitates rapid transportation and just-in-time manufacturing, often favoring regional sourcing.

Criteria for Selecting API Suppliers

When selecting a bulk API supplier, stakeholders should evaluate:

Regulatory compliance: Certifications such as cGMP (current Good Manufacturing Practice) and ISO standards.
Quality assurance: Purity, radionuclide purity, and sterility testing capabilities.
Manufacturing capacity: Ability to supply consistent, scalable quantities aligned with clinical and commercial demand.
Traceability and documentation: Comprehensive batch documentation and stability data.
Supply chain reliability: Geographic proximity, logistical capabilities, and contingency planning.

Emerging Trends and Alternatives

Emerging manufacturing approaches involve cyclotron-based isolation of I-131 and the development of novel radiolabeling techniques that increase API yield and stability. These innovations could augment existing API supply sources or open new markets.

Regulatory Considerations in API Sourcing

Regulatory compliance remains paramount. APIs must meet stringent standards set by agencies such as the FDA or EMA, including batch consistency, radionucline purity, and traceability. Importers and end-users should verify supplier accreditation and conduct audits where applicable.

Supply Chain Strategies

To mitigate risks associated with API sourcing, organizations may consider:

Establishing multiple supply agreements across different regions.
Collaborating with CMOs that have dedicated radiopharmaceutical manufacturing capacity.
Investing in local or regional API production facilities to reduce logistics-related vulnerabilities.
Maintaining adequate inventory to buffer against supply interruptions, considering the decay characteristics of I-131.

Conclusion

The sourcing of bulk Iobenguane sulfate I-131 requires navigating a complex landscape governed by technical, regulatory, and logistical factors. Leading suppliers are generally niche radiopharmaceutical manufacturers with proven GMP compliance and scalable production capabilities. Given the critical role of API quality in therapeutic efficacy and diagnostic accuracy, establishing robust supplier relationships and continuous oversight is indispensable for stakeholders involved in radiopharmaceutical production and distribution.

Key Takeaways

The primary sources for bulk Iobenguane sulfate I-131 are specialized radiopharmaceutical manufacturers with GMP certification.
Regional manufacturing hubs in North America, Europe, and Asia-Pacific serve as key suppliers, albeit with varying capacities.
Supply chain resilience relies on diversification, regional sourcing, and inventory management tailored to the isotope's half-life.
Strict regulatory adherence and quality control are non-negotiable in API sourcing.
Technological innovations in radiochemistry are likely to influence future API manufacturing landscapes.

FAQs

1. How does the short half-life of I-131 impact API sourcing strategies?
The 8-day half-life necessitates rapid logistics and just-in-time manufacturing. Suppliers must operate close to treatment centers or have efficient distribution networks to deliver fresh API while maintaining quality.

2. Are there synthetic alternatives to Iobenguane sulfate I-131 for neuroendocrine tumor diagnosis and therapy?
Currently, I-131 MIBG remains the standard. However, emerging radiopharmaceuticals and targeted therapies, such as peptide receptor radionuclide therapy (PRRT) with Lutetium-177, are evolving alternatives.

3. What regulatory approvals are essential for I-131 API suppliers?
Suppliers must hold certifications like cGMP, ISO, and regional licensing approvals demonstrating adherence to safety, purity, and manufacturing standards.

4. Can non-radioactive iodine-131 isotopes be used for API manufacturing?
Yes, but the radiolabeled form (I-131 MIBG) is required for clinical applications. The key is sourcing high-purity I-131 isotopic material suitable for radiolabeling.

5. How can organizations mitigate risks in sourcing radioactive APIs?
Diversify suppliers, develop local manufacturing capabilities, maintain strategic stockpiles, and establish clear regulatory compliance and quality assurance protocols.

References

[1] Solnes, L., et al. "Radiopharmaceutical Manufacturing and Supply Chain Considerations." Journal of Nuclear Medicine Technology, 2022.

[2] European Medicines Agency. "Guidelines on the Manufacture and Quality Control of Radiopharmaceuticals." EMA, 2021.

[3] U.S. Food and Drug Administration. "GMP for Radiopharmaceuticals." FDA, 2020.

[4] IAEA. "Radioisotope Production." International Atomic Energy Agency, 2019.

[5] Smith, J., & Lee, K. "Advances in Radiolabeling Techniques for MIBG." Nuclear Medicine Communications, 2021.

Bulk Pharmaceutical API Sources for IOBENGUANE SULFATE I 131